We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$163M
AUM Growth
-$69.7M
Cap. Flow
-$67.5M
Cap. Flow %
-41.51%
Top 10 Hldgs %
62.79%
Holding
55
New
8
Increased
9
Reduced
9
Closed
21

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$6.42M
2
TERN
Terns Pharmaceuticals
TERN
+$4.99M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.79M
4
CBAY
Cymabay Therapeutics
CBAY
+$3.86M
5
KROS icon
Keros Therapeutics
KROS
+$3.74M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$17.8M
2
RLMD icon
Relmada Therapeutics
RLMD
+$13.5M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$9.84M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$8.45M
5
BLU
BELLUS Health Inc.
BLU
+$7.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
26
Iovance Biotherapeutics
IOVA
$2.77B
$982K 0.6%
153,639
– –
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.53B
$982K 0.6%
+93,500
New +$831K
PYXS icon
28
Pyxis Oncology
PYXS
$238M
$897K 0.55%
669,158
– –
RZLT icon
29
Rezolute
RZLT
$453M
$869K 0.54%
420,000
+855
+0.2% +$1.6K
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$683K 0.42%
6,000
+2,000
+50% +$166K
PRTA icon
31
Prothena Corp
PRTA
$449M
$560K 0.34%
+9,300
New +$545K
ELVN icon
32
Enliven Therapeutics
ELVN
$4.31B
$182K 0.11%
+11,126
New +$178K
KNTE
33
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$30.5K 0.02%
5,000
– –
NUVB.WS
34
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.1K 0.01%
90,832
– –
ALLK
35
DELISTED
Allakos
ALLK
– –
-192,500
Closed -$1.18M
ALT icon
36
Altimmune
ALT
$585M
– –
-125,000
Closed -$1.6M
BMEA icon
37
Biomea Fusion
BMEA
$90.4M
– –
-1,000
Closed -$10K
ESPR
38
DELISTED
Esperion Therapeutics
ESPR
– –
-30,000
Closed -$201K
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
– –
-290,000
Closed -$3.03M
GOSS icon
40
Gossamer Bio
GOSS
$87.2M
– –
-284,500
Closed -$3.41M
IDYA icon
41
IDEAYA Biosciences
IDYA
$3.49B
– –
-10,000
Closed -$149K
MIST icon
42
Milestone Pharmaceuticals
MIST
$147M
– –
-597,026
Closed -$5.49M
MRUS
43
DELISTED
Merus
MRUS
– –
-59,000
Closed -$1.18M
RLMD icon
44
Relmada Therapeutics
RLMD
$564M
– –
-365,618
Closed -$13.5M
RLMD icon
45
PUT
Relmada Therapeutics
RLMD
$564M
– –
-200,000
Closed -$7.4M
SWTX
46
DELISTED
SpringWorks Therapeutics
SWTX
– –
-5,000
Closed -$143K
TRVI icon
47
Trevi Therapeutics
TRVI
$2.63B
– –
-36,302
Closed -$56K
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.24B
– –
-272,500
Closed -$9.84M
ZNTL icon
49
Zentalis Pharmaceuticals
ZNTL
$356M
– –
-5,000
Closed -$108K
NGM
50
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-7,500
Closed -$98K
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Acuta Capital Partners held 55 positions worth $163M, down 30% from $232M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners withdrew a net $67.5M in Q4 2022, closing 21 positions and reducing 9 holdings. Its most notable exit was Relmada Therapeutics, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Mersana Therapeutics worth $5.57M.

  • Acuta Capital Partners's largest Q4 2022 buy was Mersana Therapeutics: 38,000 shares worth $5.57M.
  • Acuta Capital Partners added most to Terns Pharmaceuticals in Q4 2022, an estimated $4.99M increase.
  • Acuta Capital Partners's biggest Q4 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $17.8M.
  • Acuta Capital Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $13.5M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $163M portfolio in Q4 2022.
  • Acuta Capital Partners opened 8 new positions and closed 21 in Q4 2022.
  • Acuta Capital Partners's portfolio value fell 30% quarter-over-quarter to $163M.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.